BioCentury
ARTICLE | Clinical News

Solosec regulatory update

January 25, 2017 2:44 AM UTC

Symbiomix submitted an NDA to FDA for Solosec secnidazole to treat bacterial vaginosis. The product is an oral granule formulation of a next-generation, 5-nitroimidazole antibiotic and has Fast Track ...

BCIQ Company Profiles

Symbiomix Therapeutics LLC